Drugs / HEC-921
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07824934 | Sep 2026 → May 2028 expected | cancer | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC-921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07824934 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT07824934 ↗ |